PACTR201803003160262
Recruiting
未知
Comparative Effectiveness of six-week treatment course of vitamin D2 and D3 in children with sickle cell anaemia in steady state: A randomized clinical Trial
Not provided0 sites154 target enrollmentMarch 3, 2018
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Not provided
- Enrollment
- 154
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Children with sickle cell anaemia aged 1 to 18 years
- •Children with 25(OH)D level below 75nmol/L
- •Children whose parents give consent
- •Children 7 years and above that assent to be part of the study
Exclusion Criteria
- •Children with established diagnosis of tuberculosis, asthma or on steroid
- •Children with established renal or kidney disease
- •Children on anticonvulsants
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole alone in non- or mildly- immunocompromised patients with Chronic Pulmonary Aspergillosis: a prospective, randomized, single blind study, (single aspergilloma excluded).MedDRA version: 20.1 Level: LLT Classification code 10022881 Term: Invasive bronchopulmonary aspergillosis System Organ Class: 100000004862Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]EUCTR2018-000972-14-FRCHU DE POITIERS224
Active, not recruiting
Not Applicable
Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.EUCTR2007-001975-12-BEPIERRE FABRE MEDICAMENT - IDPF200
Active, not recruiting
Not Applicable
Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.Mild Cognitive ImpairmentMedDRA version: 9.1Level: LLTClassification code 10009846Term: Cognitive impairmentEUCTR2007-001975-12-FIPIERRE FABRE MEDICAMENT - IDPF210
Active, not recruiting
Phase 1
Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.Mild Cognitive ImpairmentMedDRA version: 9.1Level: LLTClassification code 10009846Term: Cognitive impairmentEUCTR2007-001975-12-FRPIERRE FABRE MEDICAMENT - IDPF200
Active, not recruiting
Phase 1
Evaluation of the effect of 6 months treatment with DC158AM on fatigue in patients with Parkinson’s disease. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.Fatigue symptoms in Parkinson's disease.MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson'sEUCTR2007-002195-34-FRPIERRE FABRE MEDICAMENT120